Literature DB >> 22798623

Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis.

Takako Iida Jones1, Jennifer C J Chen, Fedik Rahimov, Sachiko Homma, Patricia Arashiro, Mary Lou Beermann, Oliver D King, Jeffrey B Miller, Louis M Kunkel, Charles P Emerson, Kathryn R Wagner, Peter L Jones.   

Abstract

Facioscapulohumeral muscular dystrophy (FSHD), the most prevalent myopathy afflicting both children and adults, is predominantly associated with contractions in the 4q35-localized macrosatellite D4Z4 repeat array. Recent studies have proposed that FSHD pathology is caused by the misexpression of the DUX4 (double homeobox 4) gene resulting in production of a pathogenic protein, DUX4-FL, which has been detected in FSHD, but not in unaffected control myogenic cells and muscle tissue. Here, we report the analysis of DUX4 mRNA and protein expression in a much larger collection of myogenic cells and muscle biopsies derived from biceps and deltoid muscles of FSHD affected subjects and their unaffected first-degree relatives. We confirmed that stable DUX4-fl mRNA and protein were expressed in myogenic cells and muscle tissues derived from FSHD affected subjects, including several genetically diagnosed adult FSHD subjects yet to show clinical manifestations of the disease in the assayed muscles. In addition, we report DUX4-fl mRNA and protein expression in muscle biopsies and myogenic cells from genetically unaffected relatives of the FSHD subjects, although at a significantly lower frequency. These results establish that DUX4-fl expression per se is not sufficient for FSHD muscle pathology and indicate that quantitative modifiers of DUX4-fl expression and/or function and family genetic background are determinants of FSHD muscle disease progression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22798623      PMCID: PMC3459465          DOI: 10.1093/hmg/dds284

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  30 in total

1.  Common epigenetic changes of D4Z4 in contraction-dependent and contraction-independent FSHD.

Authors:  Jessica C de Greef; Richard J L F Lemmers; Baziel G M van Engelen; Sabrina Sacconi; Shannon L Venance; Rune R Frants; Rabi Tawil; Silvère M van der Maarel
Journal:  Hum Mutat       Date:  2009-10       Impact factor: 4.878

2.  DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy.

Authors:  Linda N Geng; Zizhen Yao; Lauren Snider; Abraham P Fong; Jennifer N Cech; Janet M Young; Silvere M van der Maarel; Walter L Ruzzo; Robert C Gentleman; Rabi Tawil; Stephen J Tapscott
Journal:  Dev Cell       Date:  2011-12-29       Impact factor: 12.270

3.  Specific loss of histone H3 lysine 9 trimethylation and HP1gamma/cohesin binding at D4Z4 repeats is associated with facioscapulohumeral dystrophy (FSHD).

Authors:  Weihua Zeng; Jessica C de Greef; Yen-Yun Chen; Richard Chien; Xiangduo Kong; Heather C Gregson; Sara T Winokur; April Pyle; Keith D Robertson; John A Schmiesing; Virginia E Kimonis; Judit Balog; Rune R Frants; Alexander R Ball; Leslie F Lock; Peter J Donovan; Silvère M van der Maarel; Kyoko Yokomori
Journal:  PLoS Genet       Date:  2009-07-10       Impact factor: 5.917

4.  Possible phenotypic dosage effect in patients compound heterozygous for FSHD-sized 4q35 alleles.

Authors:  M Wohlgemuth; R J Lemmers; E L van der Kooi; M J van der Wielen; P G van Overveld; H Dauwerse; E Bakker; R R Frants; G W Padberg; S M van der Maarel
Journal:  Neurology       Date:  2003-10-14       Impact factor: 9.910

5.  Somatic mosaicism in FSHD often goes undetected.

Authors:  Richard J L F Lemmers; Michiel J R van der Wielen; Egbert Bakker; George W Padberg; Rune R Frants; Silvère M van der Maarel
Journal:  Ann Neurol       Date:  2004-06       Impact factor: 10.422

6.  Hypomethylation is restricted to the D4Z4 repeat array in phenotypic FSHD.

Authors:  J C de Greef; M Wohlgemuth; O A Chan; K B Hansson; D Smeets; R R Frants; C M Weemaes; G W Padberg; S M van der Maarel
Journal:  Neurology       Date:  2007-09-04       Impact factor: 9.910

Review 7.  Facioscapulohumeral muscular dystrophy.

Authors:  Rabi Tawil
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

8.  Facioscapulohumeral muscular dystrophy: new insights from compound heterozygotes and implication for prenatal genetic counselling.

Authors:  Isabella Scionti; Greta Fabbri; Chiara Fiorillo; Giulia Ricci; Francesca Greco; Roberto D'Amico; Alberto Termanini; Liliana Vercelli; Giuliano Tomelleri; Michelangelo Cao; Lucio Santoro; Antonio Percesepe; Rossella Tupler
Journal:  J Med Genet       Date:  2012-01-03       Impact factor: 6.318

9.  Gene expression during normal and FSHD myogenesis.

Authors:  Koji Tsumagari; Shao-Chi Chang; Michelle Lacey; Carl Baribault; Sridar V Chittur; Janet Sowden; Rabi Tawil; Gregory E Crawford; Melanie Ehrlich
Journal:  BMC Med Genomics       Date:  2011-09-27       Impact factor: 3.063

10.  The D4Z4 macrosatellite repeat acts as a CTCF and A-type lamins-dependent insulator in facio-scapulo-humeral dystrophy.

Authors:  Alexandre Ottaviani; Sylvie Rival-Gervier; Amina Boussouar; Andrea M Foerster; Delphine Rondier; Sabrina Sacconi; Claude Desnuelle; Eric Gilson; Frédérique Magdinier
Journal:  PLoS Genet       Date:  2009-02-27       Impact factor: 5.917

View more
  97 in total

1.  The FSHD2 gene SMCHD1 is a modifier of disease severity in families affected by FSHD1.

Authors:  Sabrina Sacconi; Richard J L F Lemmers; Judit Balog; Patrick J van der Vliet; Pauline Lahaut; Merlijn P van Nieuwenhuizen; Kirsten R Straasheijm; Rashmie D Debipersad; Marianne Vos-Versteeg; Leonardo Salviati; Alberto Casarin; Elena Pegoraro; Rabi Tawil; Egbert Bakker; Stephen J Tapscott; Claude Desnuelle; Silvère M van der Maarel
Journal:  Am J Hum Genet       Date:  2013-09-26       Impact factor: 11.025

2.  Role of the Chromosome Architectural Factor SMCHD1 in X-Chromosome Inactivation, Gene Regulation, and Disease in Humans.

Authors:  Chen-Yu Wang; Harrison Brand; Natalie D Shaw; Michael E Talkowski; Jeannie T Lee
Journal:  Genetics       Date:  2019-08-16       Impact factor: 4.562

3.  Human skeletal muscle xenograft as a new preclinical model for muscle disorders.

Authors:  Yuanfan Zhang; Oliver D King; Fedik Rahimov; Takako I Jones; Christopher W Ward; Jaclyn P Kerr; Naili Liu; Charles P Emerson; Louis M Kunkel; Terence A Partridge; Kathryn R Wagner
Journal:  Hum Mol Genet       Date:  2014-01-22       Impact factor: 6.150

4.  Exome sequencing identifies a novel SMCHD1 mutation in facioscapulohumeral muscular dystrophy 2.

Authors:  Satomi Mitsuhashi; Steven E Boyden; Elicia A Estrella; Takako I Jones; Fedik Rahimov; Timothy W Yu; Basil T Darras; Anthony A Amato; Rebecca D Folkerth; Peter L Jones; Louis M Kunkel; Peter B Kang
Journal:  Neuromuscul Disord       Date:  2013-08-31       Impact factor: 4.296

Review 5.  Facioscapulohumeral muscular dystrophy as a model for epigenetic regulation and disease.

Authors:  Charis L Himeda; Takako I Jones; Peter L Jones
Journal:  Antioxid Redox Signal       Date:  2014-12-04       Impact factor: 8.401

6.  Transcriptional profiling in facioscapulohumeral muscular dystrophy to identify candidate biomarkers.

Authors:  Fedik Rahimov; Oliver D King; Doris G Leung; Genila M Bibat; Charles P Emerson; Louis M Kunkel; Kathryn R Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-17       Impact factor: 11.205

7.  Myogenic enhancers regulate expression of the facioscapulohumeral muscular dystrophy-associated DUX4 gene.

Authors:  Charis L Himeda; Céline Debarnot; Sachiko Homma; Mary Lou Beermann; Jeffrey B Miller; Peter L Jones; Takako I Jones
Journal:  Mol Cell Biol       Date:  2014-03-17       Impact factor: 4.272

8.  DUX4-induced gene expression is the major molecular signature in FSHD skeletal muscle.

Authors:  Zizhen Yao; Lauren Snider; Judit Balog; Richard J L F Lemmers; Silvère M Van Der Maarel; Rabi Tawil; Stephen J Tapscott
Journal:  Hum Mol Genet       Date:  2014-05-26       Impact factor: 6.150

9.  Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy.

Authors:  Jonathan Oliva; Scott Galasinski; Amelia Richey; Amy E Campbell; Marvin J Meyers; Neal Modi; Jun Wen Zhong; Rabi Tawil; Stephen J Tapscott; Francis M Sverdrup
Journal:  J Pharmacol Exp Ther       Date:  2019-06-12       Impact factor: 4.030

10.  The DUX4 homeodomains mediate inhibition of myogenesis and are functionally exchangeable with the Pax7 homeodomain.

Authors:  Darko Bosnakovski; Erik A Toso; Lynn M Hartweck; Alessandro Magli; Heather A Lee; Eliza R Thompson; Abhijit Dandapat; Rita C R Perlingeiro; Michael Kyba
Journal:  J Cell Sci       Date:  2017-09-21       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.